Disagreement over how to justify starting materials selection prompts EMA action
This article was originally published in SRA
Executive Summary
The European Medicines Agency is attempting to clarify what information drug companies should include in their marketing authorization dossiers to justify the selection of starting materials in light of 2012 International Conference on Harmonisation guideline Q11 that covers this topic.